Uncategorized

Lawmakers Tuesday night released the full text of a bipartisan agreement to fund the government through March. It could also reshape the pharmacy supply chain by reforming how controversial drug middlemen do business.

Industry experts said profit pressures and M&A contributed to job cuts. They said layoffs will likely continue into next year, but some expect the cuts to slow.

With about one month before inauguration day, check out a roundup of MedTech Dive’s coverage on what President-elect Donald Trump’s new administration means for medical device companies.

AbbVie’s blockbuster Humira held 105 patents, shielding the anti-inflammatory drug from biosimilar competition for more than 20 years. Proposed reforms could help prevent companies from extending exclusivity with such patent thickets.

The bankrupt health system had sought a buyer for the facility for months without success, according to court documents.

BioSpace Senior Editor Annalee Armstrong reflects on the year that was, and what’s to come in 2025.

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.

Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.

Las aceitunas rellenas de anchoa son uno de los tesoros de la cocina actual. Mezcla la riqueza de las aceitunas y el carácter fuerte de las anchoas. Con raíces profundamente arraigadas en la tradición mediterránea, ofrecen a las personas no solo una nueva experiencia de s …

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.